Helft Gérard, Dambrin Grégoire, Zaman Azfar, Le Feuvre Claude, Barthélémy Olivier, Beygui Farzin, Favereau Xavier, Metzger Jean-Philippe
Department of Cardiology, Institut de Cardiologie - GH Pitié-Salpétrière, AP-HP, Université Pierre et Marie Curie, Paris, France.
Catheter Cardiovasc Interv. 2009 Jan 1;73(1):44-7. doi: 10.1002/ccd.21758.
To assess safety and feasibility of using radial artery access for percutaneous coronary intervention (PCI) in patients on oral anticoagulation without interrupting therapy.
The radial artery approach for PCI is intuitively attractive for patients receiving chronic oral anticoagulation with vitamin K antagonists (VKAs) but little data exist concerning feasibility or safety of this approach in this population. The main advantage of this strategy would be to avoid bridging therapy with heparin that increases risk of thrombotic and bleeding events.
In this prospective observational study, 50 consecutive patients referred for coronary angiography underwent PCI without interrupting oral anticoagulant therapy. The main outcome measures were bleeding and thrombotic complications.
The indications for permanent oral anticoagulation were as follows: atrial fibrillation in 62%, mechanical prosthesis in 24%, and venous thromboembolism in 14%. Seventy-two percent were elective cases and 28% presented with acute coronary syndromes. PCI was performed with an INR range of 1.4-3.4 with mean of 2.2 +/- 0.6. Seventy-six percent of the patients were on dual antiplatelet therapy before the procedure. No thrombotic events or excess bleeding were observed at 1 month. Only one patient had a minor hemorrhage 8 days after procedure.
This series suggests that for patients treated with VKAs, the use of radial artery access is feasible and safe for PCI on dual antiplatelet therapy without interrupting oral anticoagulant treatment.
评估在口服抗凝治疗的患者中不中断治疗而采用桡动脉途径进行经皮冠状动脉介入治疗(PCI)的安全性和可行性。
对于接受维生素K拮抗剂(VKA)长期口服抗凝治疗的患者,PCI的桡动脉途径直观上具有吸引力,但关于该途径在这一人群中的可行性或安全性的数据很少。这种策略的主要优点是避免使用肝素进行桥接治疗,而肝素会增加血栓形成和出血事件的风险。
在这项前瞻性观察性研究中,50例连续接受冠状动脉造影的患者在不中断口服抗凝治疗的情况下接受了PCI。主要观察指标为出血和血栓形成并发症。
永久性口服抗凝的指征如下:62%为房颤,24%为机械瓣膜置换,14%为静脉血栓栓塞。72%为择期病例,28%为急性冠状动脉综合征。PCI时国际标准化比值(INR)范围为1.4 - 3.4,平均为2.2±0.6。76%的患者在手术前接受双联抗血小板治疗。1个月时未观察到血栓形成事件或过度出血。仅1例患者在术后8天发生轻度出血。
该系列研究表明,对于接受VKA治疗的患者,在不中断口服抗凝治疗的情况下,采用桡动脉途径进行双联抗血小板治疗的PCI是可行且安全的。